With Five Deals In Two Months, TorreyPines Scrambling To Preserve A Future
This article was originally published in The Pink Sheet Daily
Executive Summary
California biotech has out-licensed virtually everything but three clinical compounds, while exiting discovery work entirely.
You may also be interested in...
Can Big Pharma Save Biotech Investors?
Want to know how bad off small biotechs are these days? Investment bankers are so desperate to unload companies, they've taken to calling on corporate development departments with lists of "wounded animals" - those companies with just a few months of cash remaining, according to a business development head at a big pharmaceutical company
Can Big Pharma Save Biotech Investors?
Want to know how bad off small biotechs are these days? Investment bankers are so desperate to unload companies, they've taken to calling on corporate development departments with lists of "wounded animals" - those companies with just a few months of cash remaining, according to a business development head at a big pharmaceutical company
Deals Of The Week: Affymetrix/Panomics, Eisai/TorreyPines, Daiichi/ArQule
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.